logo-loader
viewVolitionRx

Full interview: VolitionRx achieves 'massive breakthrough' in its Nu.Q Capture cancer diagnostic technology

VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the cancer diagnostic company has achieved a 'massive breakthrough' in the development of its Nu.Q Capture cancer-detection technology, which is the ability to enrich nucleosomes.

Reynolds says enriching nucleosomes effectively 'sweeps away' the background noise, achieving a better signal-to-noise ratio, which creates a potential licensing opportunity from other companies in the liquid biopsy space that specialize in sequencing.

Quick facts: VolitionRx

Price: 5.43 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $223.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash. ''Total cash in hand that gives...

on 9/5/19

2 min read